Novo Nordisk Healthcare AG
Novo Nordisk Rare Disease is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Formerly known as Novo Nordisk Biopharm, the franchise was renamed in 2022 to highlight the Company’s strategic direction and new areas of focus. The franchise employs more than 3,300 people around the world.
Novo Nordisk Rare Disease is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders and employs more than 3,300 people around the world.